Vanguard Group’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Vanguard Group’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-198,154	Closed	-$38.6K	–	4505
2023 Q4	$38.6K	Sell	198,154 -301,743	-60%	-$65.6K	﹤0.01%	4389
2023 Q3	$183K	Buy	499,897 +61,418	+14%	+$41.4K	﹤0.01%	4266
2023 Q2	$474K	Hold	438,479	–	–	﹤0.01%	4134
2023 Q1	$307K	Buy	438,479 +3,700	+0.9%	+$4.35K	﹤0.01%	4242
2022 Q4	$480K	Buy	434,779 +135	+0%	+$199	﹤0.01%	4111
2022 Q3	$765K	Buy	434,644 +101,098	+30%	+$184K	﹤0.01%	4082
2022 Q2	$520K	Buy	333,546 +49,151	+17%	+$82.2K	﹤0.01%	4284
2022 Q1	$563K	Buy	284,395 +80,633	+40%	+$279K	﹤0.01%	4375
2021 Q4	$947K	Buy	+203,762	New	+$1.67M	﹤0.01%	4282

Other funds holding BTTX

CIAS

Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Vanguard Group's BTTX Position: Q1 2024 in Review

Vanguard Group sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 198,154 shares — an estimated $38.6K sold.

Vanguard Group first reported a position in BTTX in Q4 2021 and held it in 9 quarters. The position peaked at $947K in Q4 2021. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

Vanguard Group reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Vanguard Group sold 198,154 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $38.6K.
Vanguard Group first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Vanguard Group's Better Therapeutics, Inc. Common Stock position peaked at $947K in Q4 2021.
3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.